Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114208 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Philipp Jansen und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Essen, Essen, Germany & German Cancer Consortium (DKTK), partner site Essen, Düsseldorf, Germany; Depa…. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Proto-Oncogene Proteins B-raf, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Essen, Essen, Germany & German Cancer Consortium (DKTK), partner site Essen, Düsseldorf, Germany; Department of Dermatology, University Hospital Bonn, Bonn. Electronic addr…
- Institute for medical informatics, biometry and epidemiology, University Hospital Essen, Essen, Germany.
- Department of Dermatology, University Hospital Essen, Essen, Germany & German Cancer Consortium (DKTK), partner site Essen, Düsseldorf, Germany.
- Hauttumorzentrum, Helios Klinikum Erfurt, Erfurt, Germany.
- Department of Dermatology, UKSH Campus Lübeck, Lübeck, Germany.
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germ…
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Jansen, P., Galetzka, W., Lodde, G. C., Standl, F., Zaremba, A., Herbst, R., Terheyden, P., Utikal, J., Pföhler, C., Ulrich, J., Kreuter, A., Mohr, P., Gutzmer, R., Meier, F., Dippel, E., Weichenthal, M., Placke, J. M., Landsberg, J., Möller, I., …, & Griewank, K. G. (2024). Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114208
Vancouver
Jansen P, Galetzka W, Lodde GC, Standl F, Zaremba A, Herbst R, et al. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114208
BibTeX
@article{Jansen2024,
author = {Jansen, Philipp and Galetzka, Wolfgang and Lodde, Georg C and Standl, Fabian and Zaremba, Anne and Herbst, Rudolf and Terheyden, Patrick and Utikal, Jochen and Pföhler, Claudia and Ulrich, Jens and Kreuter, Alexander and Mohr, Peter and Gutzmer, Ralf and Meier, Friedegund and Dippel, Edgar and Weichenthal, Michael and Placke, Jan-Malte and Landsberg, Jennifer and Möller, Inga and Sucker, Antje and Paschen, Annette and Hadaschik, Eva and Zimmer, Lisa and Livingstone, Elisabeth and Schadendorf, Dirk and Ugurel, Selma and Stang, Andreas and Griewank, Klaus G},
title = {Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114208}
}
EUVIMED